Asia Pacific Asthma Drugs Market
市场的增长归因于哮喘患病率的上升和机遇随着生物制剂的商业化正在推动哮喘药物市场的增长。然而，未满足的医疗需求正在阻碍市场增长。
许多哮喘患者观察到，识别和避免诱因、每日吸入或口服控制药物以及在症状出现时使用快速缓解吸入器就足够了以控制哮喘。然而，这些药物不足以治疗某些人的哮喘。几种新药，即“生物制剂”，最近已获得许可用于治疗中度至重度哮喘。生物制剂与其他药物不同，因为它针对与哮喘有关的特定抗体、分子或细胞。因此，生物制剂被称为精准治疗或个性化治疗。
生物制剂是一种从活体细胞（例如细菌或小鼠）中提取的药物，专门针对人类的特定分子。抗体、炎症化学物质和细胞受体是哮喘生物制剂的目标。通过靶向这些分子，生物制剂试图破坏导致炎症的过程，从而导致哮喘症状。
生物制剂被给予那些尽管每天服用正常控制药物但仍然出现症状的患者。哮喘控制不佳的症状包括反复入院、急诊室就诊或需要口服类固醇来缓解病情恶化；晚上醒来呼吸困难；需要每天或每周数次速效缓解药物，例如沙丁胺醇；并需要每天或每周数次速效缓解药物，例如沙丁胺醇。在开生物制剂之前，临床医生应确保患者按照处方服用所有其他控制药物，避免任何潜在的触发因素，并治疗任何其他可能加剧哮喘的疾病。
生物制剂的主要优点是减少许多哮喘急性发作，包括急诊室就诊、住院治疗和口服类固醇的需求。生物制剂的其他优点还包括减少哮喘症状、降低其他控制药物的剂量以及减少缺课和缺勤的情况。生物制剂可改善哮喘患者的生活质量。据报道，一些生物制剂可以帮助严重哮喘患者改善肺功能。
目前，有五种治疗哮喘的生物制剂已获批准——omalizumab、美泊利珠单抗、瑞利珠单抗、贝那利珠单抗和杜匹鲁单抗。奥马珠单抗是一种针对 IgE 过敏抗体的抗体。美泊利珠单抗、瑞利珠单抗和贝那利珠单抗靶向嗜酸性粒细胞，这是一种在过敏性炎症中发挥作用的细胞。 Dupilumab 是一种单克隆抗体，针对引起过敏性炎症的两种分子的受体。医生将进行筛查测试，例如血液检查或环境过敏原皮肤点刺测试，以确定哪种生物制剂是治疗哮喘的最佳方法。奥马珠单抗被批准用于六岁或以上的患者。除 reslizumab 外，所有生物制剂均被批准用于 12 岁的个体。 18岁及以上的成年人可以使用reslizumab。
生物制剂已在试验中被证明非常安全，并且有一些副作用。此外，生物制剂比其他控制药物更昂贵，但由于需求增加、新生物制剂的推出和大规模生产，价格可能会下降。
亚太地区哮喘药物市场细分
亚太地区哮喘药物市场按药物划分为快速缓解药物和长期控制药物。根据给药途径，市场分为吸入型、预充式注射器/小瓶等。 根据分销渠道，亚太哮喘药物市场分为网上药房、医院药房和零售药房。按国家/地区划分，市场分为印度、中国、日本、澳大利亚、韩国和亚太地区其他地区。
阿斯利康；梯瓦制药工业有限公司；
勃林格殷格翰国际有限公司、葛兰素史克公司、默克公司Co., Inc.、Koninklijke Philips NV、赛诺菲、
辉瑞公司 (Arena Pharmaceutical GmbH)、诺华公司和雅培都是亚太地区哮喘领域的领先公司毒品市场。
Strategic insights for Asia Pacific Asthma Drugs involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.
| Report Attribute | Details |
|---|---|
| Market size in 2021 | US$ 3,783.73 Million |
| Market Size by 2028 | US$ 5,806.55 Million |
| Global CAGR (2021 - 2028) | 6.3% |
| Historical Data | 2019-2020 |
| Forecast period | 2022-2028 |
| Segments Covered |
By 药物治疗
|
| Regions and Countries Covered | 亚太地区
|
| Market leaders and key company profiles |
The regional scope of Asia Pacific Asthma Drugs refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.
The Asia Pacific Asthma Drugs Market is valued at US$ 3,783.73 Million in 2021, it is projected to reach US$ 5,806.55 Million by 2028.
As per our report Asia Pacific Asthma Drugs Market, the market size is valued at US$ 3,783.73 Million in 2021, projecting it to reach US$ 5,806.55 Million by 2028. This translates to a CAGR of approximately 6.3% during the forecast period.
The Asia Pacific Asthma Drugs Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Asia Pacific Asthma Drugs Market report:
The Asia Pacific Asthma Drugs Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Asia Pacific Asthma Drugs Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Asia Pacific Asthma Drugs Market value chain can benefit from the information contained in a comprehensive market report.
Office No. 1011, First floor, Farena Corporate Park, Magarpatta-Mundhwa road, Pune - 411028, Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For Asia Pacific Asthma Drugs Market
